Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Gemcitabine Hydrochloride and Cisplatin with or without Nab-Paclitaxel in Treating Patients with Newly Diagnosed Advanced Biliary Tract Cancers

This phase III trial studies how well gemcitabine hydrochloride and cisplatin given with or without nab-paclitaxel work in treating patients with newly diagnosed biliary tract cancers that have spread to other places in the body. Drugs used in chemotherapy, such as gemcitabine hydrochloride, cisplatin, and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not known if giving gemcitabine hydrochloride and cisplatin with or without nab-paclitaxel may work better at treating biliary tract cancers.
Liver, Pancreatic
Phase III
Adults
Chemotherapy - cytotoxic
Cisplatin, Gemcitabine, Nab-Paclitaxel
Goff, Laura
National
Vanderbilt University
04-24-2019
Treatment
ECOGGIS1815
NCT03768414

Eligibility

Not Available
Not Available
NO
Inclusion Criteria:

Patients must have histologically or cytologically confirmed intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer * NOTE: Pathology report must be uploaded in Rave. Histology report must be consistent with an adenocarcinoma with pancreaticobiliary primary assuming there are no pancreatic lesions and other primaries are ruled out per local standard

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: